Steven Prestrelski is CSO at XERIS PHARMACEUTICALS INC (XERS). They have made 6 open-market trades across 1 company since 2018, most recently 2023-01-31.
CIK 0001744027
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| XERS | 719,780 | $7.5M |
Shares reported on the most recent Form 4, priced at the 2023-02-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| XERS | SELL · 10b5-1 | 2022-02-22 | 2022-02-24 | $2.42 | $27K | -1.3% | +12.1% | -17.9% |
| XERS | SELL · 10b5-1 | 2021-04-12 | 2021-04-13 | $4.07 | $41K | +2.3% | -18.4% | -2.6% |
| XERS | SELL | 2021-01-13 | 2021-01-15 | $6.01 | $60K | -3.5% | +19.3% | -28.5% |
| XERS | SELL | 2021-01-11 | 2021-01-12 | $5.72 | $57K | -6.4% | +10.9% | -34.3% |
| XERS | SELL | 2020-01-13 | 2020-01-14 | $5.50 | $55K | +0.5% | -30.6% | -69.4% |
| XERS | SELL | 2019-04-11 | 2019-04-12 | $9.56 | $96K | -2.1% | +28.5% | +30.6% |
| XERS | SELL | 2019-01-14 | 2019-10-16 | $12.01 | $453K | -9.2% | -2.8% | -30.0% |
| XERS | SELL | 2018-12-26 | 2019-01-02 | $15.82 | $497K | -1.0% | -19.9% | -43.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.